Response to: 'Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities' by Bossuyt et al

Ann Rheum Dis. 2019 Aug;78(8):e77. doi: 10.1136/annrheumdis-2018-213841. Epub 2018 Jun 23.

Authors

David S Pisetsky¹, Diane M Spencer¹, Peter E Lipsky², Brad H Rovin³

Affiliations

¹ Department of Medicine and Immunology, Duke University Medical Center and Medical Research Service, VA Medical Center, Durham, North Carolina, USA.
² RILITE Research Institute, Charlottesville, Virginia, USA.
³ Division of Nephrology, The Ohio State University, Columbus, Ohio, USA.

PMID: 29936440
DOI: 10.1136/annrheumdis-2018-213841

No abstract available

Keywords: disease activity; systemic lupus erythematosus; treatment.

Publication types

Letter
Comment

MeSH terms

Antibodies, Antinuclear*
Biological Assay
Humans
Lupus Erythematosus, Systemic*
Oxidation-Reduction

Substances

Antibodies, Antinuclear